Junshi Biosciences Enters Final Analysis Phase of Phase 3 Clinical Trial for Loqtorzi and Lenvima Combination Therapy as First-Line Treatment for Hepatocellular Carcinoma
A New Paradigm for First-Line Hepatocellular Carcinoma Treatment
Shanghai Junshi Biosciences' PD-1 immune checkpoint inhibitor, Loqtorzi (toripalimab), and Eisai's multi-target tyrosine kinase inhibitor (TKI), Lenvima (lenvatinib), combination therapy has reached the final analysis stage of its Phase 3 clinical trial (NCT04523493). This trial is designed to demonstrate survival benefits compared to a placebo control group in patients with advanced hepatocellular carcinoma (HCC) who have not previously received systemic therapy. The combination of an immune checkpoint inhibitor and a targeted therapy reflects the latest trend in cancer treatment, aiming to maximize therapeutic response by altering the tumor microenvironment. If it proves superior to existing treatments, it is expected to bring about a significant change in the first-line treatment landscape for liver cancer.
A Rigorously Designed, Double-Blind, Randomized Trial
To minimize bias, the study employs a 2:1 randomization ratio and a double-blind design, further enhancing the objective reliability of the clinical data. The experimental group receives the combination of Loqtorzi and Lenvima, while the control group receives Lenvima and a placebo, allowing for a direct comparison of efficacy and safety between the two groups. To pass the stringent approval criteria of global regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), it is essential to secure clear and valid data from such a randomized controlled trial. The industry believes that the well-designed nature of this trial will be a key advantage when applying for regulatory approval in the future.
Market Expansion Strategy Through Global Partnerships
In 2021, Junshi Biosciences entered into a major licensing agreement with Coherus BioSciences for the North American rights, laying the foundation for its entry into the global market. This deal includes an upfront payment of $150 million (USD) and milestone payments of $380 million (USD), as well as royalties of 20% of sales, demonstrating the commercial value of Loqtorzi in the market. Having already received its first approval as a treatment for nasopharyngeal carcinoma (NPC) from the U.S. FDA in October 2023, its experience in overcoming regulatory hurdles is a significant advantage. If successful in expanding the indication to hepatocellular carcinoma, the growth of North American market sales is expected to accelerate through the distribution network of its partner, Coherus.
Changing the Landscape of the Competitive First-Line Liver Cancer Treatment Market
The global hepatocellular carcinoma treatment market is predicted to grow rapidly to approximately $33.8 billion (USD) by 2035, representing a large unmet medical need. Currently, the market is dominated by Roche's Tecentriq (atezolizumab) and Avastin (bevacizumab) combination therapy, and AstraZeneca's Imfinzi (durvalumab) and Imjudo (tremelimumab) combination therapy as standard of care. The Loqtorzi and Lenvima combination therapy must demonstrate superior progression-free survival (PFS) and overall survival (OS) data compared to the existing Lenvima monotherapy in order to gain market acceptance. With the final data release imminent, global pharmaceutical companies and investors are paying close attention to whether this combination will emerge as a 'game changer' that disrupts the monopoly of existing standard treatments.
This Phase 3 trial represents a critical inflection point for Junshi Biosciences, as it determines whether Loqtorzi can become a key player in the rapidly growing first-line treatment market for advanced hepatocellular carcinoma, which is projected to reach $33.8 billion by 2035. Success in the trial will increase the likelihood of achieving additional milestones under the $150 million upfront and $380 million milestone payment agreement with its co-development partner, Coherus BioSciences, thereby contributing to its financial stability. In the medium to long term, it could disrupt the competitive landscape dominated by Roche's Tecentriq + Avastin and AstraZeneca's Imfinzi + Imjudo by offering a more affordable and convenient option. For researchers and clinicians, the trial provides high-quality Phase 3 data on the synergistic effects of PD-1 inhibitors and multi-target TKIs, offering a new combination option.
Source: ClinicalTrials.gov (api_ct)